To determine the cardioprotective effects of RNLS independent of renal function, CKD mice were treated with AAV9-carrying RNLS under the control of the cardiomyocyte-specific cardiac troponin T (cTnT) promoter (AAV9-cTnT-Rnls) or the vectors at 2 weeks (Figure 2A). Here, TNNT2 is linked to chronic kidney disease.